Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Overview of attention for article published in New England Journal of Medicine, August 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 79 news outlets
blogs: 2 blogs
policy: 2 policy sources
twitter: 80 X users
patent: 9 patents

facebook: 5 Facebook pages
wikipedia: 3 Wikipedia pages
reddit: 1 Redditor
f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 416 Mendeley

So far, Altmetric has seen 95 X posts from 80 X users, with an upper bound of 1,615,778 followers.

Either master regulators (IRF3, ARL2BP, ZBTB17, and ATRX) https://t.co/bD77v7KHey or a 3-gene signature ( WNT10A, DUSP1, and ETV7) https://t.co/2mRCDBnsUZ

@VPrasadMDMPH First in class etc etc. We need to know at least why the pts are resistant while in vitro gave positive signal for the trial. Maybe there is something to improve. The trial for myeloma tried to develop a classifier but the sample size was …

RT @btfoundation: Dr. Luciano Costa @End_myeloma from @uabmedicine will talk about treating transplant patients at our #MultipleMyeloma con…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 91 additional X posts.